U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H13NO8S2.2Na
Molecular Weight 481.4101
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM PICOSULFATE ANHYDROUS

SMILES

c1ccnc(c1)C(c2ccc(cc2)OS(=O)(=O)[O-])c3ccc(cc3)OS(=O)(=O)[O-].[Na+].[Na+]

InChI

InChIKey=GOZDTZWAMGHLDY-UHFFFAOYSA-L
InChI=1S/C18H15NO8S2.2Na/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25;;/h1-12,18H,(H,20,21,22)(H,23,24,25);;/q;2*+1/p-2

HIDE SMILES / InChI

Molecular Formula C18H13NO8S2
Molecular Weight 435.4306
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Picosulfuric acid (as sodium picosulfate) is a contact laxative, which is used in combination with: magnesium oxide, and anhydrous citric acid for cleansing of the colon as a preparation for colonoscopy in adults. Sodium picosulfate is a prodrug. It has no significant direct physiological effect on the intestine. But it is hydrolyzed by colonic bacteria to form an active metabolite: bis-(p-hydroxy-phenyl)-pyridyl-2-methane, BHPM, which acts directly on the colonic mucosa to stimulate colonic peristalsis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PREPOPIK

Approved Use

PREPOPIK (sodium picosulfate, magnesium oxide and anhydrous citric acid) for oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults.

Launch Date

1.34231045E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.1 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
2.3 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
21.3 ng/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
209 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
275 ng × h/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.3 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
7.4 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
10 h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEACETYLBISACODYL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
Analytical control of a pharmaceutical formulation of sodium picosulfate by capillary zone electrophoresis.
2001 Feb 10
Investigation of the effects of YM-31636, a novel 5-HT3 receptor agonist, on defecation in normal and constipated ferrets.
2001 Jul 20
Oral sodium phosphate solution: a review of its use as a colorectal cleanser.
2004
Retrospective study of long-term treatment with sodium picosulfate.
2004 Apr
Drugs in palliative care: results from a representative survey in Germany.
2004 Mar
Screening procedure for detection of stimulant laxatives and/or their metabolites in human urine using gas chromatography-mass spectrometry after enzymatic cleavage of conjugates and extractive methylation.
2005 Apr
Bioavailability of glycyrrhizin from Shaoyao-Gancao-Tang in laxative-treated rats.
2005 Oct
Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study.
2006 Jun
Is bowel preparation required before cystoplasty in children?
2006 Oct
[Distigmine bromide improves chronic intestinal pseudo-obstruction in a case of MELAS].
2007 Apr
Interaction between Shaoyao-Gancao-Tang and a laxative with respect to alteration of paeoniflorin metabolism by intestinal bacteria in rats.
2007 Aug
Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy.
2007 Dec 3
Randomized clinical trial comparing sodium picosulfate with mannitol on the preparation FOR colonoscopy in hospitalized patients.
2007 Jul-Sep
Comparison of colon-cleansing methods in preparation for colonoscopy--comparative efficacy of solutions of mannitol, sodium picosulfate and monobasic and dibasic sodium phosphates.
2008
OTC laxative use of sodium picosulfate â results of a pharmacy-based patient survey (cohort study).
2008 Feb
Commonly used bowel preparations have significant and different effects upon cell proliferation in the colon: a pilot study.
2008 Nov 14
Changes of intestinal mucosal and plasma PYY in a diarrhea model rat and influence of loperamide as the treatment agent for diarrhea.
2008 Sep
[Optimization of perioperative management in laparoscopic hernioplasty].
2008 Sep
Comparison of two common outpatient preparations for colonoscopy in children and youth.
2009
Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser.
2009
Full-laxative versus minimum-laxative fecal-tagging CT colonography using 64-detector row CT: prospective blinded comparison of diagnostic performance, tagging quality, and patient acceptance.
2009 Jul
A multicentre, observational study of sodium picosulfate and magnesium citrate as a precolonoscopy bowel preparation.
2009 Oct
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation.
2010 Apr
A review of laxative therapies for treatment of chronic constipation in older adults.
2010 Dec
Laxative activities of Mareya micrantha (Benth.) Müll. Arg. (Euphorbiaceae) leaf aqueous extract in rats.
2010 Feb 16
Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation.
2010 Sep
Patents

Sample Use Guides

PREPOPIK ((sodium picosulfate, magnesium oxide, and anhydrous citric acid), supplied as a powder, must be reconstituted with cold water right before its use. There are two dosing regimens, each requires two separate dosing times: The preferred method is the “Split Dose” method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy. The alternative method is the “Day Before” method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy). Additional fluids must be consumed after every dose in both dosing regimens. Instruct patients to consume only clear liquids (no solid food or milk) on the day before the colonoscopy up until 2 hours before the time of the colonoscopy. Instruct patients that if they experience severe bloating, distention, or abdominal pain following the first dose, delay the second dose until their symptoms resolve.
Route of Administration: Oral
In Vitro Use Guide
Sodium picosulfate was biotransformed by intestinal flora that produced a novel sulfotransferase (not sulfatase). The biotransformation was activated by adding phenolic compounds such as phenol, acetaminophen and flavonoids. The enzyme activity related to this biotransformation was the highest in the contents of the caecum region of the intestine. The enzyme activity was 3.0 umole/hr/g wet feces in humans and 0.75 in rats (pH 8.0). The optimal pH was 9.0. The sulfotransferase activity was assayed in reaction mixture consisting of 60 uL of 50 mM PNS (occasionally sodium picosulfate), tyramine and 0.2 ml of the enzyme solution. Sulfatase activity was measured under the assay conditions for he sulfotransferase acitivity without the addition of the acceptor tyramine.
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:35:11 UTC 2021
Edited
by admin
on Sat Jun 26 12:35:11 UTC 2021
Record UNII
VW106606Y8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM PICOSULFATE ANHYDROUS
Common Name English
SODIUM PICOSULFATE [INN]
Common Name English
PICOSULFATE SODIUM ANHYDROUS
Common Name English
4,4'-(2-PYRIDYLMETHYLENE)DIPHENOL BIS(HYDROGEN SULPHATE) DISODIUM SALT
Common Name English
PICOSULFATE SODIUM [MI]
Common Name English
SODIUM PICOSULPHATE ANHYDROUS
Common Name English
4,4'-(2-PYRIDYLMETHYLENE)DIPHENOL BIS(HYDROGEN SULFATE) DISODIUM SALT
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29697
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
Code System Code Type Description
INN
2265
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY
EVMPD
SUB34329
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY
DRUG BANK
DB09268
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY
FDA UNII
VW106606Y8
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY
EVMPD
SUB10569MIG
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY
EPA CompTox
10040-45-6
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY
PUBCHEM
68654
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY
CAS
10040-45-6
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY
ECHA (EC/EINECS)
233-120-9
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY
NCI_THESAURUS
C143005
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY
MERCK INDEX
M8788
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY Merck Index
EVMPD
SUB126862
Created by admin on Sat Jun 26 12:35:11 UTC 2021 , Edited by admin on Sat Jun 26 12:35:11 UTC 2021
PRIMARY
Related Record Type Details
SUBSTANCE->BASIS OF STRENGTH
PARENT -> SALT/SOLVATE
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
ACTIVE MOIETY